Omeros Corp. (OMER)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put OMER beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 50% in its worst 12-month stretch.
View RiskOMER’s case rests on YARTEMLEA’s commercial launch, though recent financial performance is steady and revenue growth is not shown. The latest quarter beat non-GAAP EPS consensus, reporting $0.02 against a $0.27 loss estimate. OMER trades at 18× sales versus a 10× peer median, near its 16× historical multiple. The price is roughly in line with forecast growth. European regulatory rejection of narsoplimab threatens its commercial prospects. A next-quarter miss probability of 26% adds risk. Peer multiples imply a price about 40% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. OMER is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering OMER (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare OMER with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| OMER Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put OMER next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
European regulatory setback for narsoplimab creates a meaningful headwind to the drug’s commercial prospects.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Commercial launch and market expansion of YARTEMLEA
Upgrade reflects confidence in Yartemlea's market potential.

Advances: Achieve positive cash flow and profitability
Profitability achievement supports growth objective.

Advances: Commercial launch and market expansion of YARTEMLEA
Interest expense and NTAP indicate progress in YARTEMLEA.

Advances: Commercial launch and market expansion of YARTEMLEA
Strong launch signals positive momentum for YARTEMLEA.
Advances: Achieve positive cash flow and profitability
Expectation of positive cash flow within 18 months is significant.